Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
Silvia Cantara(University of Siena), Paolo Toti(University of Siena), Eugenio Bertelli(University of Siena), Maria Grazia Castagna(University of Siena), Lucia Brilli(University of Siena), Furio Pacini, Rossella Occhini(Azienda Usl 8 Arezzo), Marì Regoli(University of Siena)
Cited by 63
Related Papers
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1
|The Journal of Clinical Endocrinology & Metabolism|1999|564
Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology
|The Journal of Clinical Endocrinology & Metabolism|2010|316
miRNA Targets: From Prediction Tools to Experimental Validation
|Methods and Protocols|2020|240
A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone Withdrawal
|The Journal of Clinical Endocrinology & Metabolism|2006|198